만성 호흡기 질환의 유병률 증가, DPI의 기술 개발, 자가 치료 지향 증가 등이 시장 확대에 기여하고 있으며, Verified Market Research의 애널리스트에 따르면, 건조 분말 흡입기 시장은 2024년 약 184억 달러에 달했고, 예측 기간 동안 244억 7,000만 달러에 도달할 것으로 추정됩니다.
호흡기 질환의 비율 증가, DPI 장치 기술 향상, 신속하고 효율적인 흡입 치료에 대한 환자 수요 등이 분말식 흡입기(DPI) 시장의 강력한 확장에 기여하고 있습니다. 이에 따라 시장은 2026-2032년까지 연평균 3.6%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.
분말식 흡입기(DPI) 시장 : 정의/개요
분말식 흡입기(DPI)는 건조 분말 형태로 폐에 약물을 투여하는 의료기기입니다. 추진제를 이용해 약물을 분출하는 일반 흡입기와 달리, DPI는 환자의 호흡을 이용해 분말을 흡입합니다. 기관지확장제, 코르티코스테로이드, 기타 약물을 호흡기에 직접 투여하는 편리하고 효과적인 방법을 제공하기 때문에 천식, 만성폐쇄성폐질환(COPD), 기타 폐질환 등 호흡기 질환 치료에 널리 사용되고 있습니다.
만성폐쇄성폐질환(COPD), 천식, 낭포성 섬유증과 같은 호흡기 질환의 유병률 증가는 DPI 시장의 중요한 촉진제입니다. 마찬가지로, Global Asthma Report 2018은 천식은 전 세계적으로 3억 3,900만 명 이상이 앓고 있다고 예측했습니다. 흡입 요법을 필요로 하는 환자 수의 확대는 효과적이고 편리한 DPI 장치에 대한 수요를 촉진하고 있습니다.
DPI는 표준 정량 흡입기(MDI) 및 분무기와 비교하여 휴대성, 사용 편의성, 추진제 제거 등 다양한 이점을 가지고 있습니다. Journal of Aerosol Medicine and Pulmonary Drug Delivery(2019)에 게재된 연구에 따르면, 환자의 89%가 DPI를 선호한다고 답했습니다. 사용 편의성과 이동성 때문에 정량 흡입기보다 DPI를 선호한다고 답했습니다.
UN에 따르면, 세계 인구는 고령화되고 있으며, 60세 이상 인구는 2050년까지 두 배로 증가할 것으로 예측됩니다. 노인은 호흡기 감염에 취약하며, 이러한 환자층에게 보다 사용하기 쉽고 효과적인 DPI 장치에 대한 수요가 증가하고 있습니다.
또한, DPI 장치의 설계, 약물 배합 및 제조 공정의 끊임없는 발전은 이러한 제품의 효율성과 사용성을 향상시키고 있습니다. 예를 들어, 다회 투여 DPI 및 호흡 작동식 DPI의 개발로 환자의 순응도와 편의성이 향상되었습니다. 예를 들어, BMJ Open에 게재된 연구에 따르면 영국에서 정량식 흡입기(MDI)의 10%를 분말식 흡입기(DPI)로 전환하면 연간 58,000톤의 이산화탄소 배출을 줄일 수 있다고 합니다.
DPI에서 효과적인 약물 전달을 위해서는 적절한 흡입 방법이 필수적이지만, 이는 어린 유아나 노인, 협응력에 문제가 있는 환자에게는 어려운 일입니다. 호흡 방법이 일정하지 않으면 폐에 약물이 덜 축적되어 치료 효과가 떨어질 수 있습니다.
안정적이고 효과적인 DPI 제제를 만드는 것은 어렵습니다. 분말은 효율적인 흡입을 위해 충분히 미세해야 하며, 동시에 최적의 분산을 위해 적절한 유동성을 가져야 합니다. 또한, 일부 약물은 흡습성이 있어 주변에서 수분을 축적하여 DPI 내 안정성과 기능에 영향을 미칠 수 있습니다.
또한, DPI는 가압식 정량 흡입기(MDI) 및 분무기와 같은 다른 흡입 기술과 경쟁하고 있으며, MDI는 사용 편의성 때문에 선호되는 반면, 분무기는 흡입 기술에 어려움을 겪는 사람이나 고용량 약물이 필요한 사람에게 적합하기 때문에 특정 부문에서 DPI 시장 성장을 제한하고 있습니다. 제한되고 있습니다.
The increasing prevalence of chronic respiratory diseases, technological developments in DPIs, and the growing inclination towards self-medication are all contributing to the market's rapid expansion. According to the analyst from Verified Market Research, the dry powder inhaler market is estimated to reach a valuation of USD 24.47 Billion over the forecast subjugating around USD 18.4 Billion valued in 2024.
The growing rates of respiratory illnesses, improved DPI device technology, and patient demand for quick and efficient inhalation treatment are all contributing to the market's strong expansion for dry powder inhalers, or DPIs. It enables the market to grow at a CAGR of 3.6% from 2026 to 2032.
Dry Powder Inhaler (DPI) Market: Definition/ Overview
A Dry Powder Inhaler (DPI) is a medical device that administers medication to the lungs in the form of dry powder. Unlike regular inhalers, which utilize a propellant to dispense medication, DPIs use the patient's breath to inhale the powder. These devices are widely used to treat respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other lung diseases, as they provide a convenient and effective way to deliver bronchodilators, corticosteroids, and other medications directly to the respiratory tract.
The rising prevalence of respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis is a significant driver of the DPI market. Similarly, the Global Asthma Report 2018 predicts that asthma affects more than 339 million individuals worldwide. The expanding number of patients requiring inhalation therapy is driving the demand for effective and convenient DPI devices.
DPIs have various advantages over standard metered-dose inhalers (MDIs) and nebulizers, including portability, convenience of use, and the elimination of propellants. These advantages make DPIs more enticing to patients, resulting in higher adoption. According to research published in the Journal of Aerosol Medicine and Pulmonary Drug Delivery (2019), 89% of patients preferred DPIs to metered-dose inhalers because of their ease of use and mobility.
The global population is aging, with the number of individuals aged 60 and older anticipated to double by 2050, according to the United Nations. Older persons are more vulnerable to respiratory infections, increasing the demand for DPI devices that are simpler to use and more effective for this patient population.
Furthermore, continuous advancements in DPI device design, medication formulations, and manufacturing processes improve the efficiency and use of these products. For example, the development of multi-dose DPIs and breath-actuated DPIs has increased patient compliance and convenience. For instance, according to a study published in BMJ Open, switching 10% of metered-dose inhalers (MDIs) to dry powder inhalers (DPIs) in the UK could reduce carbon emissions by 58,000 tons annually.
Proper inhaling methods are essential for effective medication delivery with a DPI, which can be challenging for small children, elderly patients, and individuals with coordination issues. Inconsistent breathing procedures cause less medication accumulation in the lungs, potentially jeopardizing therapy efficacy.
Creating stable and effective DPI compounds is difficult. The powder should be fine enough for efficient inhalation while also having appropriate flow characteristics for optimum dispersion. Furthermore, some drugs are hygroscopic, accumulating moisture from their surroundings, affecting their stability and function within a DPI.
Furthermore, DPIs compete with other inhalation technologies, such as pressurized metered dosage inhalers (MDIs) and nebulizers. MDIs are recommended for their ease of use, whereas nebulizers are appropriate for people suffering from inhalation techniques or requiring high medicine doses, which limits market growth for DPIs in certain segments.
According to VMR Analysis, the capsule-based segment is estimated to hold the largest market share during the forecast period. Capsule-based DPIs are designed to be simple and user-friendly for patients. They frequently have a simple loading mechanism that requires little effort to prepare the dose. Furthermore, capsule-based devices are small and lightweight, which improves portability and convenience for patients on the move.
Capsule-based DPIs provide better dosage precision than other device types. The pre-metered capsules ensure that each dose includes the exact amount of medication, reducing the risk of under- or overdosing. This precision contributes to improved therapeutic efficacy and patient outcomes.
Furthermore, DPI capsules work well with a wide range of respiratory drugs, including bronchodilators, corticosteroids, and combination therapy. This adaptability enables healthcare providers to modify treatment strategies to particular patient demands, resulting in the widespread use of capsule-based devices.
The chronic obstructive pulmonary disease (COPD) segment is estimated to dominate the dry powder inhaler market during the forecast period. COPD is a prominent cause of illness and mortality worldwide, with a large and increasing prevalence. The World Health Organization estimates that over 65 million people suffer from COPD globally. This vast patient population creates a demand for effective inhalation medicines for COPD therapy, such as DPIs.
COPD is primarily controlled with inhalation medicines, which effectively deliver pharmaceuticals to the lungs. DPIs have been a popular alternative among COPD patients due to their portability, convenience, and ability to administer exact medicine doses precisely to the afflicted parts of the respiratory system.
Additionally, there is an increasing emphasis on preventative healthcare strategies for respiratory disorders such as COPD. DPIs serve an important role in providing targeted drug delivery, reducing exacerbations, and improving overall health outcomes for COPD patients, which has fueled their acceptance in this segment.
According to VMR Analyst, North America is estimated to dominate the dry powder inhaler market during the forecast period. Asthma and chronic obstructive pulmonary disease (COPD) are common respiratory disorders in North America, particularly in the United States. According to the Centers for Disease Control and Prevention, more than 25 million Americans have asthma, while an estimated 16 million people in the United States suffer from COPD. This vast patient population increases the demand for effective inhalation medicines such as DPIs.
North America, led by the United States, has a well-developed healthcare system that provides extensive access to innovative medical technologies and treatments. This allows for the adoption of innovative DPI equipment and promotes the growth of the DPI market in the region. The presence of important market participants, as well as ongoing R&D initiatives, contribute to the region's dominant position.
Furthermore, the availability of favorable payment rules for respiratory drugs and equipment increases patient access to DPIs. This, combined with the population's strong spending power, makes North America an appealing market for DPI producers, driving overall regional market growth.
The Asia Pacific region is estimated to exhibit the highest growth within the dry powder inhaler market during the forecast period. The Asia-Pacific region includes a sizable and expanding patient population suffering from respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. According to the Global Asthma Report 2018, the Asia-Pacific region has the most people with asthma, accounting for more than 175 million cases. This high illness burden drives the region's adoption of effective inhalation medicines such as DPIs.
Governments in the Asia-Pacific region are boosting their investments in healthcare access and infrastructure, particularly in emerging countries. This, together with increased awareness of respiratory disorders and the benefits of sophisticated inhalation devices among healthcare professionals and patients, is driving the DPI market in this region.
Furthermore, leading multinational pharmaceutical and medical device businesses are increasing their presence and manufacturing capabilities in Asia-Pacific to meet rising demand. Also, strategic collaborations between major corporations and local players are permitting the launch of innovative DPI products adapted to the needs of the regional market, which is driving the Asia-Pacific DPI market forward.
The dry powder inhaler (DPI) market is characterized by fierce competition among leading competitors, which is driven by ongoing innovation and developments in device technology. Additionally, the rising prevalence of respiratory disorders has prompted significant investment in R&D, resulting in the launch of new formulations and combination medicines.
Some of the prominent players operating in the dry powder inhaler (DPI) market include:
GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim International GmbH, Novartis AG, Teva Pharmaceutical Industries Ltd., Cipla Inc., Merck & Co., Inc., 3M Pharmaceuticals, Hovione, MannKind Corpo.
In February 2021, Catalent Inc. purchased Acorda Therapeutics Inc., expanding its DPI production capabilities and adding a commercial-stage pharmaceutical to its portfolio. This acquisition highlights the growing importance of DPI treatments in respiratory and neurological illnesses.
In April 2019, Hovione Technology acquired the rights to develop and commercialize Dr. Klaus-Dieter Beller's Papillon DPI, a revolutionary and cost-effective dry powder inhaler technology.